Xtant Medical Holdings (XTNT) Research & Development (2010 - 2025)

Xtant Medical Holdings (XTNT) has reported Research & Development for 16 consecutive years, with $11.7 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Research & Development fell 1.21% year-over-year to $11.7 million in Q3 2025; TTM through Sep 2025 was $46.2 million, a 5.83% decrease from a year earlier, with the FY2024 full-year figure at $49.2 million, up 28.03% from the prior year.
• Research & Development was $11.7 million for Q3 2025 at Xtant Medical Holdings, up from $11.6 million in the prior quarter.
• Over five years, Research & Development peaked at $13.2 million in Q2 2024 and troughed at $4.9 million in Q1 2021.
• A 5-year average of $8.7 million and a median of $8.7 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development retreated 24.29% in 2021 and surged 98.63% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $5.3 million in 2021, then rose by 9.77% to $5.8 million in 2022, then surged by 98.63% to $11.6 million in 2023, then gained by 0.86% to $11.7 million in 2024, then grew by 0.53% to $11.7 million in 2025.
• The last three Research & Development figures came in at $11.7 million (Q3 2025), $11.6 million (Q2 2025), and $11.2 million (Q1 2025), per Business Quant data.